Paradigm Biopharmaceuticals Activates Additional Hong Kong Site For Global Phase Three Knee Osteoarthiritis Study

MT Newswires Live

03/20

Paradigm Biopharmaceuticals (ASX:PAR) said an additional international clinical trial site in Hong Kong, the Hong Kong Center for Clinical Research, for its global phase three clinical study evaluating injectable pentosan polysulfate sodium in patients with knee osteoarthritis was activated, according to a Friday Australian bourse filing.

The site started screening patients, with the study designed to enrol 466 participants globally.

Three clinical trial sites in Moldova are expected to be activated in the coming weeks.

Its shares rose 2% in recent trading on Friday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2620203940"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620203940\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620203940?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 09:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620203940","market":"fut","top_or_hot":-1,"title":"Paradigm Biopharmaceuticals Activates Additional Hong Kong Site For Global Phase Three Knee Osteoarthiritis Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) said an additional international clinical trial site in Hong Kong, the Hong Kong Center for Clinical Research, for its global phase three clinical study evaluating injectable pentosan polysulfate sodium in patients with knee osteoarthritis was activated, according to a Friday Australian bourse filing.</p><p>The site started screening patients, with the study designed to enrol 466 participants globally.</p><p>Three clinical trial sites in Moldova are expected to be activated in the coming weeks.</p><p>Its shares rose 2% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Paradigm Biopharmaceuticals Activates Additional Hong Kong Site For Global Phase Three Knee Osteoarthiritis Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParadigm Biopharmaceuticals Activates Additional Hong Kong Site For Global Phase Three Knee Osteoarthiritis Study\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-20 09:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) said an additional international clinical trial site in Hong Kong, the Hong Kong Center for Clinical Research, for its global phase three clinical study evaluating injectable pentosan polysulfate sodium in patients with knee osteoarthritis was activated, according to a Friday Australian bourse filing.</p><p>The site started screening patients, with the study designed to enrol 466 participants globally.</p><p>Three clinical trial sites in Moldova are expected to be activated in the coming weeks.</p><p>Its shares rose 2% in recent trading on Friday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"醫藥生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2620203940","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620203940","pubTimestamp":1773970163,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Paradigm Biopharmaceuticals  said an additional international clinical trial site in Hong Kong, the Hong Kong Center for Clinical Research, for its global phase three clinical study evaluating injectable pentosan polysulfate sodium in patients with knee osteoarthritis was activated, according to a Friday Australian bourse filing.The site started screening patients, with the study designed to enrol 466 participants globally.Three clinical trial sites in Moldova are expected to be activated in the coming weeks.Its shares rose 2% in recent trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7067":"生物科技","PAR.AU":"PARADIGM BIOPHARMACEUTICALS"},"translate_title":"Paradigm Biopharmaceuticals启用额外的香港站点进行全球三期膝关节骨关节炎研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAR.AU":1},"content_text":"Paradigm Biopharmaceuticals (ASX:PAR) said an additional international clinical trial site in Hong Kong, the Hong Kong Center for Clinical Research, for its global phase three clinical study evaluating injectable pentosan polysulfate sodium in patients with knee osteoarthritis was activated, according to a Friday Australian bourse filing.The site started screening patients, with the study designed to enrol 466 participants globally.Three clinical trial sites in Moldova are expected to be activated in the coming weeks.Its shares rose 2% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}